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Abstract
Background: Pulmonary rehabilitation is an effective therapeutic intervention for people with chronic respiratory
disease. However, fewer than 5% of eligible individuals receive pulmonary rehabilitation on an annual basis, largely
due to limited availability of services and difficulties associated with travel and transport. The Rehabilitation Exercise
At Home (REAcH) study is an assessor-blinded, multi-centre, randomised controlled equivalence trial designed to
compare the efficacy of home-based telerehabilitation and traditional centre-based pulmonary rehabilitation in
people with chronic respiratory disease.
Methods: Participants will undertake an 8-week group-based pulmonary rehabilitation program of twice-weekly
supervised exercise training, either in-person at a centre-based pulmonary rehabilitation program or remotely from
their home via the Internet. Supervised exercise training sessions will include 30 min of aerobic exercise (cycle and/
or walking training). Individualised education and self-management training will be delivered. All participants will be
prescribed a home exercise program of walking and strengthening activities.
Outcomes will be assessed by a blinded assessor at baseline, after completion of the intervention, and 12-months
post intervention. The primary outcome is change in dyspnea score as measured by the Chronic Respiratory
Questionnaire – dyspnea domain (CRQ-D). Secondary outcomes will evaluate the efficacy of telerehabilitation on 6-
min walk distance, endurance cycle time during a constant work rate test, physical activity and quality of life.
Adherence to pulmonary rehabilitation between the two models will be compared. A full economic analysis from a
societal perspective will be undertaken to determine the cost-effectiveness of telerehabilitation compared to
centre-based pulmonary rehabilitation.
Discussion: Alternative models of pulmonary rehabilitation are required to improve both equity of access and
patient-related outcomes. This trial will establish whether telerehabilitation can achieve equivalent improvement in
outcomes compared to traditional centre-based pulmonary rehabilitation. If efficacious and cost-effective, the
proposed telerehabilitation model is designed to be rapidly deployed into clinical practice.
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Background
Chronic respiratory diseases, including chronic obstruct-
ive pulmonary disease (COPD), interstitial lung diseases
(ILD), bronchiectasis and chronic asthma, contribute 7%
to the global burden of disease [1]. Chronic respiratory
diseases are the third leading cause of death worldwide,
and account for 10% of all disability adjusted life years
lost due to disability alone [2]. This level of disability is
second only to that of cardiovascular disease, including
stroke [2]. People with chronic respiratory disease
experience repeated need for hospitalisation, reduced
quality of life and life expectancy, poor exercise toler-
ance and physical functioning, and increased incidence
of anxiety and depression [3].
Pulmonary rehabilitation is a proven, effective strategy
to achieve clinically important gains in exercise and
functional capacity, symptoms and quality of life [4]
across a variety of chronic respiratory diseases, including
COPD [5], bronchiectasis [6], ILD [7] and asthma [8].
Participation in pulmonary rehabilitation also reduces
hospitalisation due to acute exacerbations of respiratory
disease [9] as well as overall healthcare utilisation [10].
Pulmonary rehabilitation is a recommended treatment
strategy for individuals with a chronic respiratory disease
in clinical guidelines across the world [4].
Despite compelling evidence for the benefit of pul-
monary rehabilitation, only a very small percentage of
eligible people ever attend a program [11]. There are
well established barriers to uptake and participation in
traditional centre-based pulmonary rehabilitation pro-
grams, both in the hospital and in the community, relat-
ing to referral practices, travel, transport, disability and
lack of program staffing [12, 13]. Such barriers dispro-
portionately compromise access to programs for patients
in rural and regional locations [14]. In light of such
obstacles, alternative modes of delivering pulmonary
rehabilitation, in addition to traditional centre-based
programs, are required to improve both equity of access
and patient-related outcomes for people with chronic
respiratory diseases and have been identified as a
research priority [15].
Home-based models of pulmonary rehabilitation have
been proposed to increase the availability and accessibility
of pulmonary rehabilitation services to patients [16–20].
Recent work has demonstrated that home-based
pulmonary rehabilitation achieves equivalent clinical out-
comes to centre-based pulmonary rehabilitation [20].
However, a disadvantage of such programs is the lack of su-
pervised exercise training. Advances in Internet technology
and accessibility have made it possible for people to receive
specialist medical care and therapeutic interventions
straight to their home. Telerehabilitation is the use of infor-
mation and communication technologies to provide clinical
rehabilitation services from a distance [21]. Using the Inter-
net, rehabilitation can be delivered directly to the patient’s
location, regardless of physical proximity to a rehabilitation
centre. Whilst telerehabilitation technology has existed for
many years, the clinical efficacy of this model is not clear.
Preliminary studies have described the use of telereh-
abilitation in COPD, using a variety of program models.
These studies suggest that telerehabilitation in COPD is
safe, with no adverse events reported [22–28]. However,
most existing trials have a number of important limita-
tions, including: the requirement for participants to
attend a health facility in order to access the telerehabili-
tion service [22]; the use of bespoke, proprietary or
poorly defined equipment to deliver telerehabilitation
and monitor vital signs [23–25, 27]; failing to include su-
pervised exercise training in the telerehabilitation model
[23, 24, 27], and limiting the scope of application to indi-
viduals with COPD. These factors limit the clinical util-
ity of previous telerehabilitation programs through
restricted access [12], and omission of an essential com-
ponent of pulmonary rehabilitation [4]. We have previ-
ously demonstrated the feasibility of a telerehabilitation
model that delivers all the essential components of pul-
monary rehabilitation into the home of people with
COPD [28]. By using readily available equipment such
as an exercise bike and a tablet computer it is possible
for people to undertake a supervised exercise training
program in their own home. However, to date, a com-
parison of the outcomes and costs of telerehabilitation
to centre-based pulmonary rehabilitation has only been
undertaken in the maintenance period post-rehabilitation
[29]. A telerehabilitation model that allows all the essential
components of pulmonary rehabilitation, specifically su-
pervised exercise training and self-management education,
to be delivered at home, using readily available equipment,
with proven clinical outcomes and comparable costs, has
the potential to dramatically change the uptake and
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accessibility of pulmonary rehabilitation for all patients
with a chronic respiratory disease.
Analysing the cost of telerehabilitation is critical to de-
termine the economic viability of implementing such a
model into clinical practice. To date, there is a lack of
evidence to support the cost-effectiveness of telerehabil-
itation, despite apparent clinical benefits in a range of
health conditions [21]. A comprehensive assessment of
the economic value of telerehabilitation needs to include
both costs to the healthcare system, including the initial
costs of equipment and its transport [30], together with
costs to the patient [31]. Telerehabilitation has the po-
tential to overcome many known barriers to pulmonary
rehabilitation participation and, if cost-effective, could
be a relevant treatment alternative across all chronic re-
spiratory diseases where rehabilitation is an accepted
therapeutic intervention.
This paper describes the protocol for the Rehabilitation
Exercise At Home (REAcH) trial – a study of telerehabil-
itation in chronic respiratory disease. The aims of the
study are to compare the: 1) clinical outcomes of telereh-
abilitation and traditional centre-based pulmonary re-
habilitation for people with a chronic respiratory disease;
2) costs of telerehabilitation and centre-based pulmonary
rehabilitation. We hypothesise that the clinical effects on
symptoms, exercise capacity, and health-related quality of
life (HRQoL) will be equivalent between pulmonary re-
habilitation models; that the proportion of participants
who complete pulmonary rehabilitation will be greater in
the telerehabilitation group; and, that telerehabilitation,
delivered using our low-cost model, will provide a cost-
effective alternative to centre-based pulmonary rehabilita-




A randomised, controlled, assessor-blinded equivalence
trial with an embedded economic evaluation will be con-
ducted at two centres in metropolitan Melbourne (Al-
fred Health and Austin Health), and one regional centre
(Wimmera Health Care Group, Horsham), Australia.
Both regional and metropolitan sites have been included
to increase the external validity of our model. The study
was approved by the Human Research Ethics Committee
at Alfred Health for all sites, and local governance ap-
provals obtained from all participating sites (Austin
Health, Wimmera Health Care Group and West Wim-
mera Health Service). The trial was registered at anzctr.
org.au (ACTRN12616000360415) on March 21, 2016.
Participants
Potential participants will be referred to pulmonary re-
habilitation at the established centre-based programs of
the participating sites, or those individuals admitted to
hospital with an exacerbation of their respiratory disease.
To be eligible for inclusion participants will: 1) have a
primary diagnosis of a chronic lung disease; 2) be aged
≥40 years; and 3) be able to read and speak English. Po-
tential participants will be excluded if they have: 1) a pri-
mary diagnosis of pulmonary hypertension or lung
cancer, as rehabilitation is not yet a well established
treatment for these diagnoses; 2) attended pulmonary re-
habilitation within the previous 18 months and had no
hospitalisations for a respiratory cause since rehabilita-
tion completion, as these patients may not achieve fur-
ther benefits; 3) oxygen desaturation resulting in
cessation of cardiopulmonary exercise testing (e.g. SpO2
< 80% during exercise on cycle ergometer), to ensure
safety of unsupervised training; 4) unstable or brittle
asthma with a hospital admission or emergency depart-
ment presentation within the preceding 3 months, to en-
sure safety of unsupervised training; 5) co-morbidities
which preclude exercise training, such as neurological or
musculoskeletal impairment; or 6) are unable to follow
verbal instructions, suffer from cognitive impairment, or
have language difficulties. Eligible participants will be
provided with written and verbal information about the
study from a clinician and/or a researcher. All partici-
pants will provide written consent. Trial participation
will have no effect on routine management of their
respiratory condition or any other healthcare requirements.
Recruitment and randomisation
Participants will be randomly allocated (1:1) to trad-
itional centre-based pulmonary rehabilitation or telereh-
abilitation. A computer-generated, block randomisation
scheme will be used with stratification for (i) recruit-
ment in stable state vs post hospitalisation for respira-
tory exacerbation; (ii) site of recruitment; and (iii)
diagnosis of ILD vs other diagnoses. Sequence gener-
ation will be performed by an individual who is inde-
pendent of the research team and randomisation will
occur using an online database. The randomisation se-
quence will be concealed from investigators. Participants
will be allocated to groups after completion of baseline
assessment. Given the nature of the intervention (exer-
cise training) participants will not be blinded to the
intervention, however all outcomes will be measured by
an independent assessor blind to group allocation. The
flow of participants through the study will be reported
according to the recommendations of the Consolidated
Standard of Reporting Trials (CONSORT) [32].
Interventions
Centre-based pulmonary rehabilitation
Participants will undergo a standard outpatient pulmon-
ary rehabilitation program at the centre where they were
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recruited, according to Australian best-practice guide-
lines [33]. This involves 8 weeks of twice-weekly super-
vised sessions in groups of 8–12 participants, supervised
by a health professional experienced in the delivery of
pulmonary rehabilitation (eg. physiotherapist, exercise
physiologist) and appropriately qualified assistants (eg.
allied health assistant, nurse). Participants will undertake
at least 30 min of lower limb aerobic training each ses-
sion, which may be completed in shorter intervals if
continuous training is limited by symptoms (eg. 3 × 10
minutes or 2 × 15 minutes). A combination of cycling
and walking will be used, with the initial walking exer-
cise intensity set at 70–80% of the speed walked on a 6-
min walk test and cycle ergometer intensity set at the
work rate equivalent to 60% of the peak oxygen uptake
(VO2) on a cardiopulmonary exercise test (CPET) [34].
Intensity of both cycle and walking training will be pro-
gressed each week with the aim of maintaining Borg dys-
pnoea scores of 3–4.Cycle training will be progressed by
5–10% of the initial workload [35] and walking speed by
0.25 or 0.5 km/hour depending on initial training speed
(< 3 km/hour or ≥ 3 km/hour respectively). Resistance
training will utilise functional activities such as sit-to-
stand from a chair and upper limb weights. Initial
weights will be prescribed as tolerated, to achieve 8–12
repetitions for 3 sets of each exercise. Once the partici-
pant achieves 3 sets of 12 repetitions then the weight
will be increased. Participants will be encouraged to per-
form an additional 3 unsupervised sessions each week,
which will be documented in a home diary that is
reviewed weekly by the supervising physiotherapist. A
record of sessions attended by each participant will be
maintained. Exercise training will be standardised across
all sites with the use of a protocol for prescription and
progression.
Telerehabilitation
Remotely supervised telerehabilitation at home will be
conducted twice a week for 8 weeks, in groups of 4–6
participants at a time, supervised by an experienced
physiotherapist. Exercise training will comprise 30 min
of lower limb aerobic training and individualised
strength training exercises. Participants will undertake a
total of 30 min of cycle training, in two or more bouts,
in each telerehabilitation session. Cycle ergometer inten-
sity for telerehabilitation participants will be set with the
same parameters as for centre-based participants, that is,
at the work rate equivalent to 60% of the peak oxygen
uptake (VO2) on a cardiopulmonary exercise test
(CPET) [34]. Intensity of cycle training will be pro-
gressed each week by 5–10% of the initial workload as
tolerated [35], based on patient symptoms. Resistance
training for the arms and legs will utilise equipment
readily available in the home environment (e.g. sit to
stand from a standard height chair, bags of rice for upper
limb weights). Resistance training will be initially pre-
scribed as tolerated, to achieve 8–12 repetitions for 3
sets of each exercise. Similar to the centre-based group,
telerehabilitation participants will also be encouraged to
perform an additional 3 unsupervised sessions each
week, which will be documented in a home diary that is
reviewed weekly by the supervising physiotherapist.
The telerehabilitation set-up will be based on our suc-
cessfully piloted model [28] using readily available equip-
ment. It will comprise a step-through exercise bike to
maximise safety (Bodyworkx A915); a tablet computer
(iPad – for relative ease of use and limited need to nego-
tiate menu functions) fixed to a stand for videoconfer-
encing; and a pulse oximeter (Nonin Palmsat 2500A;
Nonin Medical Inc., Plymouth, Minnesota, USA) to
monitor SpO2 and heart rate during training and at rest.
The oximeter will not use Bluetooth but will be posi-
tioned such that the display is visible to the supervising
physiotherapist throughout the session. Videoconferenc-
ing will be via Zoom videoconferencing software (San
Jose, California, USA) that enables all participants to see
and speak to each other. To ensure safety and under-
standing of equipment operation and the exercise pro-
gram, the initial training session and establishment of
the home exercise program will occur during a home
visit by a physiotherapist.
Fidelity of the exercise training intervention for both
groups will be facilitated through regular staff training,
audit of exercise prescription and progression, and as-
sessment of participant engagement [36].
Disease-specific education and collaborative self-
management training will be delivered to participants
in both groups according to international guidelines
[4]. To standardise provision of information, partici-
pants in both groups will receive self-management
education resources from Lung Foundation Australia
in the form of a printed book and brochure detailing
the location of online resources [37]. These resources
have been developed to enable people with chronic
respiratory diseases to undertake the educational
component of pulmonary rehabilitation at their con-
venience. Self-management education for all partici-
pants will include long-term exercise planning and,
for patients with COPD or asthma, education regard-
ing identifying and managing an acute exacerbation.
Additional topics relating to self-care in chronic
respiratory disease, such as airway clearance tech-
niques and strategies for maintaining a healthy diet
will also be addressed where participants identify a
relevant health goal. After the 8-week rehabilitation
program, all participants in both groups will be en-
couraged to continue with a regular exercise regimen.
All participants will be offered the opportunity to join
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a supervised exercise maintenance program to promote
ongoing exercise adherence, in line with national stan-
dards [33]. The proportion of each group that accept a
referral and attend a program will be documented.
Outcome measures Demographic details of age, gender,
diagnosis, body mass index (BMI) and lung function will
be collected at baseline. A maximal CPET using cycle
ergometry with expired gas analysis will be completed as
part of the baseline assessment to establish a work rate
for an endurance cycle test (see secondary outcomes).
Attendance rates at training sessions will be documented
at the end of the intervention period and compared
between the centre-based and telerehabilitation groups,
with an a priori definition of pulmonary rehabilitation
adherence (i.e. program completion) as undertaking a
minimum of 70% of planned pulmonary rehabilitation
sessions [38].
Participants will undertake assessment of clinical
outcome measures at baseline, end intervention and
after 12-months follow-up (see Fig. 1). The following
measures will be recorded:
Primary outcome The Chronic Respiratory Disease
Questionnaire (CRQ) is a disease specific measure of
HRQoL for people with chronic respiratory disease [39].
The CRQ scores the domains of dyspnea, fatigue, mas-
tery and emotional function. The primary outcome will
be change in CRQ dyspnea domain (CRQ-D) from base-
line to end intervention. The CRQ-D is a valid measure
of HRQoL and is responsive to change with pulmonary
rehabilitation in people with chronic respiratory diseases
including COPD [40], bronchiectasis [41] and ILD [42].
Secondary outcomes Exercise capacity will be mea-
sured using both the 6-min walk distance (6MWD) and
endurance cycle time. The 6MWD will be measured
using the 6-min walk test which is a validated measure
of functional exercise capacity [43], and is responsive to
change following pulmonary rehabilitation in people
with chronic respiratory diseases [44, 45]. Two tests will
be completed at each assessment time-point according
to standard procedures and the best distance used for
analysis [43]. Endurance cycle time will be measured
during a constant work rate exercise test, performed
at 75% of the peak work rate on the baseline CPET.
Endurance cycle time is highly responsive to thera-
peutic interventions in people with chronic respira-
tory disease [46, 47].
The CRQ domains of fatigue, mastery and emotional
function, reflecting HRQoL, will be reported as secondary
outcomes. The SF-36v2, a validated generic quality of life
measure will be used to derive a preference-based meas-
ure of utility, the SF-6D, for economic analyses [48].
Self-efficacy will be measured using the Pulmonary
Rehabilitation Adapted Index of Self Efficacy (PRAISE)
tool, a reliable and sensitive measure of self-efficacy for
patients attending pulmonary rehabilitation [49].
Dyspnea will be measured using the Modified Medical
Research Council scale [50].
Anxiety and depression will be evaluated using the
Hospital Anxiety and Depression Scale [51]. Anxiety and
depression are common comorbidities in people with
chronic respiratory disease and can be ameliorated with
pulmonary rehabilitation [4].
Physical activity levels will be measured objectively
using a wrist-worn activity monitor over seven days
(GeneActiv; ActivInsights Ltd., Kimbolton, Cambridge-
shire, United Kingdom). The GeneActiv is a tri-axial
accelerometer that is validated for the assessment of
free-living activity in healthy people [52] and has been
used to assess physical activity in people with chronic
Fig. 1 Participant schedule. Legend: + = completed; − = not completed; 6MWT = six minute walk test; CPET = cardiopulmonary exercise test; ECT
= endurance cycle test
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respiratory disease [53]. Data will be collected and stored
as raw acceleration in g units (m/s2) for offline analysis.
Time (minutes) per day spent in sedentary, light,
moderate and vigorous physical activity will be reported.
Economic evaluation
Economic evaluation will take a societal perspective [54].
Economic evaluation will incorporate costs for all stake-
holders involved, including participants’ out-of-pocket
costs associated with health care services, and the costs
of health services, including intervention costs. To facili-
tate documentation of personal health care costs, partici-
pants will be contacted by telephone every month
during the 12-month follow-up period to document self-
reported health care utilisation and to encourage
completion of the monthly diary. Individual-level data
for outcomes of Quality-Adjusted Life Years (QALYs),
CRQ-D scores and costs will be compared to assess the
incremental impact of telerehabilitation compared to
traditional centre-based pulmonary rehabilitation. To
compare differences in costs with differences in QALYs
the SF6D score, which determines an individual’s self-
valuation of health state at a specific time-point and is
generated from the SF36-v2, will be converted into
QALYs [55]. In addition, a separate assessment of cost
effectiveness will also be undertaken by comparing the
change in CRQ-D scores from baseline to end rehabilita-
tion to the incremental costs of the intervention.
Direct costs of telerehabilitation may be higher than
those for centre-based pulmonary rehabilitation, due to
capital expenditure for equipment, but these may be
accompanied by savings in the form of averted expend-
iture on health service use. Thus we will also calculate
the (internal) rate of monetary return from investing in
the intervention, which compares the difference in costs
of health service use associated with telerehabilitation
and centre-based rehabilitation to initial outlay for infra-
structure [30]. For this purpose, any savings from lower-
ing health system costs will be assessed over a time
horizon of 12-months [30]. Sensitivity analyses will
capture variations in cost of establishing telerehabilita-
tion in rural versus urban settings in Australia.
Statistical analysis
Sample size
If there is truly no difference in the change in the
dyspnea domain of the CRQ between telerehabilitation
or traditional centre-based pulmonary rehabilitation at
the end of the 8 week intervention, then 128 participants
(64 in each group) are required to be 80% sure that the
95% confidence interval will exclude a difference in
means of 2.5 points or more. This is the minimal
important difference (MID) for the CRQ-D [56] and as-
sumes a standard deviation of the change in CRQ-D of
4.8 points [57]. A total of 142 participants will be rando-
mised to allow for 10% attrition. It is anticipated that
recruitment will be evenly distributed across sites.
This sample size will also give sufficient power for
secondary outcomes:
6-min walk distance (6MWD): if there is truly no
difference in 6MWD at the completion of 8-weeks of
centre-based pulmonary rehabilitation or telerehabilita-
tion, a total of 108 participants will be required to
ensure that the 95% confidence interval excludes a dif-
ference in group means of 30 m or more [43], assuming
a standard deviation of change in 6MWD of 53 m [58].
Endurance Cycle Time: if there is truly no difference
between telerehabilitation and centre-based pulmonary
rehabilitation in change in constant work rate endur-
ance time on cycle ergometer, then 52 participants
are required to be 80% sure that the 95% confidence
interval will exclude a difference in means of 150 s
or more. This is the MID for endurance time for
patients with COPD [59] and assumes a standard
deviation of 184 s [59].
Pulmonary rehabilitation adherence (program
completion): data from our centres indicate that only
65% people who are referred to pulmonary
rehabilitation take up the referral and complete the
program. Previous studies have documented
completion rates for telerehabilitation programs of over
90% [23, 60]. Using a conservative estimate of 85%
completion, 128 patients will be required to detect a
difference in completion rates between
telerehabilitation and traditional pulmonary
rehabilitation.
Analysis
Continuous variables will be analysed by fitting linear
mixed models, controlling for recruitment centre and
baseline values as required. The proportion of partici-
pants who attend for at least 70% of the program will be
compared between groups using a chi-squared test and
the relative risk of non-completion will be determined.
All data will be analysed by intention-to-treat. A per-
protocol analysis will also be conducted to reduce the
risk of Type 1 error, as recommended in the CONSORT
Extension for reporting of non-inferiority and equiva-
lence trials [61]. Alpha will be set at 0.05.
Data integrity and management
Data will be stored on a purpose-built online database
(www.adeptrs.com), with encryption, password protec-
tion and restricted access. No identifying information
will be stored in the online database.
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Withdrawal
A participant will be considered to have withdrawn from
the study when consent is revoked. If this occurs, no
further assessments will be performed. Participants will
be informed that data collected up to the time of
withdrawal will form part of the study results unless
permission is expressly declined. Withdrawn participants
will not be replaced. Protocol violations will not con-
stitute grounds for withdrawal. Study withdrawal will
not have any impact on care provided by any of the
participating sites.
Monitoring
The trial will be monitored by an independent Data
Safety Monitoring Board (DSMB) comprising a respira-
tory physician and two clinical research physiotherapists,
with consultation with a statistician as required. The
DSMB will review data relating to the primary outcome
(CRQ-D) as well as 6MWD, endurance cycle time and
Hospital Anxiety and Depression Scale scores. Data will
be presented to the DSMB in a blinded fashion. The
DSMB will initially review data at a time 6 months from
the commencement of recruitment. Any serious adverse
events will be notified immediately to the overseeing
ethics committee (Alfred Health) and the relevant site
governance committee, as well as to the DSMB. If
there are concerns about the safety of participants,
the DSMB will make a recommendation to the trial
steering committee about continuing, stopping, or
modifying the trial.
Discussion
Pulmonary rehabilitation is a key recommended compo-
nent of the non-pharmacological management of indi-
viduals with chronic respiratory disease [4], yet limited
access to programs prevents the widespread application
of its benefits. This study will compare both the clinical-
and cost-effectiveness of delivering pulmonary reha-
bilitation via telerehabilitation, using readily available
consumer devices and equipment, to a traditional
centre-based program.
The telerehabilitation model under investigation
directly addresses access barriers for both individual
patients and the health system. By delivering pulmonary
rehabilitation directly into the homes of people with
chronic respiratory disease issues of transport, travel, their
associated costs and weather could be negated [13, 62]. By
improving ease of access, more individuals may have the
opportunity to develop an informed and positive percep-
tion of the benefits of pulmonary rehabilitation. Reduced
healthcare utilisation has also been reported following
completion of pulmonary rehabilitation [63], and thus im-
plementation of telerehabilitation programs has the poten-
tial to positively impact on healthcare expenditure.
Unlike previous studies [23–25, 27] the telerehabilita-
tion model under investigation uses equipment that is
familiar to clinicians and patients, requires little tech-
nical support, is scalable, and has the potential to be
easily implemented into clinical practice. Telerehabilita-
tion can be delivered any time and from any place,
further extending access to patients who live away from
metropolitan centres. By providing supervised exercise
training in this way, pulmonary rehabilitation could be
accessed in locations where specialist services would
ordinarily be unavailable [64]. The remote supervision of
exercise training in this telerehabilitation model is a key
feature frequently unavailable in models of pulmonary
rehabilitation not based in a healthcare setting. In a re-
cent study of home-based pulmonary rehabilitation, 80%
of individuals who did not wish to take part in the study
declined because they wanted to attend the supervised
pulmonary rehabilitation group [20]. By providing super-
vised exercise remotely, individuals who would otherwise
be reluctant to exercise without the support of a health-
care professional may be more inclined to participate.
The purpose of this study conforms with policy state-
ments to encourage the investigation of alternative models
of pulmonary rehabilitation delivery in order to enhance
implementation, access and delivery of pulmonary
rehabilitation [15]. If this study demonstrates that telereh-
abilitation has equivalent clinical outcomes to centre-
based pulmonary rehabilitation, and is cost-effective, this
model has the potential to significantly increase service
availability and accessibility through increased options for
pulmonary rehabilitation delivery.
Trial status
Recruitment commenced in August 2016 and is continuing.
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